FITC Anti-CD19 抗体 [CB19] (ab1167)
Key features and details
- FITC Mouse monoclonal [CB19] to CD19
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
製品の概要
-
製品名
FITC Anti-CD19 antibody [CB19]
CD19 一次抗体 製品一覧 -
製品の詳細
FITC Mouse monoclonal [CB19] to CD19 -
由来種
Mouse -
標識
FITC. Ex: 493nm, Em: 528nm -
種交差性
交差種: Human -
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C. -
バッファー
Preservative: 0.1% Sodium azide
Constituent: 0.5% BSA -
Concentration information loading... -
ポリ/モノ
モノクローナル -
クローン名
CB19 -
ミエローマ
unknown -
アイソタイプ
IgG1 -
軽鎖の種類
unknown -
研究分野
関連製品
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
アプリケーション
追加情報
Characterization of leukemias and lymphomas in human lysed whole peripheral blood or mononuclear cells separated by density gradient.
CD19 (FITC) immunofluorescence analysis can be performed on a flow cytometerequipped with an excitation source of 488nm and fitted with logarithmic amplifiers.
10µl ofCD19 (FITC) is sufficient for labelling of 1x106 cells.
CD19 (FITC) immunofluorescence analysis can be performed on a flow cytometerequipped with an excitation source of 488nm and fitted with logarithmic amplifiers.
10µl ofCD19 (FITC) is sufficient for labelling of 1x106 cells.
ターゲット情報
-
機能
Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. -
関連疾患
Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low. -
配列類似性
Contains 2 Ig-like C2-type (immunoglobulin-like) domains. -
翻訳後修飾
Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation. -
細胞内局在
Membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 930 Human
- Omim: 107265 Human
- SwissProt: P15391 Human
- Unigene: 652262 Human
-
別名
- Antibody deficiency due to defect in CD19 antibody
- Antibody deficiency due to defect in CD19, included antibody
- AW495831 antibody
see all
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (3)
ab1167 は 3 報の論文で使用されています。
- Toyoshima K et al. Analysis of circulating tumor cells derived from advanced gastric cancer. Int J Cancer 137:991-8 (2015). Flow Cyt ; Human . PubMed: 25622566
- Bradbury LE et al. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol 149:2841-50 (1992). PubMed: 1383329
- Carter RH & Fearon DT CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105-7 (1992). PubMed: 1373518